Abatacept Versus Tumor Necrosis Factor Inhibitors on Mortality and Medical Utilizations in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease: a Large-scale Real-world Retrospective Cohort Study

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2024 Aug 12

PMID 39133368

Authors

Po-Cheng Shih

Chih-Cheng Lai

Qing-Hua Zou

Shiow-Ing Wang

Xiang-Yang Huang

James Cheng Chung Wei

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis is a chronic inflammatory disease, and interstitial lung disease is one of the important extra-articular manifestations. There is limited evidence comparing abatacept (ABA) and tumor necrosis factor inhibitors (TNFi) regarding the risk of mortality among patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD). The aim of this study is to investigate the risk of mortality in patients with RA-ILD treated with ABA compared to TNFi. This retrospective cohort study utilized TriNetX electronic health record database. We enrolled patients who were diagnosed with RA-ILD and had received a new prescription for either ABA or TNFi. Patients were categorized into two cohorts based on their initial prescription. The primary outcome was all-cause mortality, and secondary outcomes were healthcare utilizations, including hospitalization, critical care services, and mechanical ventilation. Subgroup analyses were performed on age, presence of anti-citrullinated peptide antibodies (ACPA), and cardiovascular risk. Among 34,388 RA-ILD patients, 895 were selected for each group (ABA and TNFi) following propensity score matching. The ABA group exhibited a higher all-cause mortality risk. (HR 1.296, 95% CI 1.006-1.671). Subgroup analysis showed a heightened risk of receiving mechanical ventilation in ABA-treated patients aged 18-64 years old (HR 1.853, 95% CI 1.002-3.426), and those with cardiovascular risk factors (HR 2.015, 95% CI 1.118-3.630). Another subgroup analysis indicated a higher risk of mortality among ABA-treated patients with positive-ACPA. (HR 4.138 95% CI 1.343-12.75). This real-world data research demonstrated a higher risk of all-cause mortality in RA-ILD patients treated with ABA compared to TNFi, particularly those aged 18-64 years, lacking cardiovascular risk factors, and positive-ACPA. ABA was associated with an increased risk of mechanical ventilation in patients aged 18-64 years and those with cardiovascular risk factors.

References

Okazaki S, Watanabe R, Harigae H, Fujii H . Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. Tohoku J Exp Med. 2020; 250(3):153-159. DOI: 10.1620/tjem.250.153. View

Alten R, Nusslein H, Mariette X, Galeazzi M, Lorenz H, Cantagrel A . Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 2017; 3(1):e000345. PMC: 5307376. DOI: 10.1136/rmdopen-2016-000345. View

Liu L, Fang C, Sun B, Bao R, Zhang H . Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: A single-center retrospective study from China. Int J Rheum Dis. 2022; 25(7):795-802. DOI: 10.1111/1756-185X.14351. View

Harrold L, Litman H, Connolly S, Kelly S, Hua W, Alemao E . Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. J Rheumatol. 2017; 45(1):32-39. DOI: 10.3899/jrheum.170007. View

Atzeni F, Cacciapaglia F, Galloways J, Manfredi A, Sakellariou G, Norton S . Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort. Autoimmun Rev. 2023; 23(2):103478. DOI: 10.1016/j.autrev.2023.103478. View

Fernandez-Diaz C, Castaneda S, Melero-Gonzalez R, Ortiz-Sanjuan F, Juan-Mas A, Carrasco-Cubero C . Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020; 59(12):3906-3916. DOI: 10.1093/rheumatology/keaa621. View

Huang S, Kronzer V, Dellaripa P, Deane K, Bolster M, Nagaraja V . Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol. 2020; 6(4):337-353. PMC: 7709915. DOI: 10.1007/s40674-020-00160-z. View

Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L . Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014; 41(4):666-72. DOI: 10.3899/jrheum.130905. View

Sanchez A, Khokhar F, Olonoff D, Carhart R . Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis. Cardiovasc Drugs Ther. 2022; 38(2):297-304. PMC: 9532807. DOI: 10.1007/s10557-022-07387-z. View

10.

Tsai J, Liu L, Chen C, Chen L, Wang S, Cheng-Chung Wei J . COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open. 2023; 9(3). PMC: 10364175. DOI: 10.1136/rmdopen-2023-003038. View

11.

Cassone G, Manfredi A, Atzeni F, Venerito V, Vacchi C, Picerno V . Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. J Clin Med. 2020; 9(1). PMC: 7019755. DOI: 10.3390/jcm9010277. View

12.

Vicente-Rabaneda E, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castaneda S . Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev. 2021; 20(6):102830. DOI: 10.1016/j.autrev.2021.102830. View

13.

Azadeh H . Association between disease-modifying antirheumatic drugs and bone turnover biomarkers. Int J Rheum Dis. 2022; 26(3):437-445. DOI: 10.1111/1756-185X.14550. View

14.

Kang E, Jin Y, Brill G, Lewey J, Patorno E, Desai R . Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. J Am Heart Assoc. 2018; 7(3). PMC: 5850244. DOI: 10.1161/JAHA.117.007393. View

15.

Nakashita T, Ando K, Takahashi K, Motojima S . Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016; 54(5):376-9. DOI: 10.1016/j.resinv.2016.03.001. View

16.

Kang E, Jin Y, Desai R, Liu J, Sparks J, Kim S . Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. Semin Arthritis Rheum. 2019; 50(3):401-408. DOI: 10.1016/j.semarthrit.2019.11.010. View

17.

Chen S, Liao K, Liu J, Kim S . Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. Arthritis Care Res (Hoboken). 2018; 72(1):9-17. PMC: 6586544. DOI: 10.1002/acr.23824. View

18.

Chen N, Diao C, Gao J, Zhao D . Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options. Semin Arthritis Rheum. 2022; 55:152004. DOI: 10.1016/j.semarthrit.2022.152004. View

19.

Fernandez-Diaz C, Loricera J, Castaneda S, Lopez-Mejias R, Ojeda-Garcia C, Olive A . Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum. 2018; 48(1):22-27. DOI: 10.1016/j.semarthrit.2017.12.012. View

20.

Hyldgaard C, Hilberg O, Pedersen A, Ulrichsen S, Lokke A, Bendstrup E . A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017; 76(10):1700-1706. DOI: 10.1136/annrheumdis-2017-211138. View